Rocket Pharmaceuticals (RCKT) Competitors $3.37 +0.24 (+7.67%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$3.38 +0.01 (+0.45%) As of 04:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RCKT vs. EVO, SRPT, NTLA, PHVS, WVE, CVAC, CALT, PAHC, AUPH, and CDTXShould you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Evotec (EVO), Sarepta Therapeutics (SRPT), Intellia Therapeutics (NTLA), Pharvaris (PHVS), WAVE Life Sciences (WVE), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Aurinia Pharmaceuticals (AUPH), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Rocket Pharmaceuticals vs. Its Competitors Evotec Sarepta Therapeutics Intellia Therapeutics Pharvaris WAVE Life Sciences CureVac Calliditas Therapeutics AB (publ) Phibro Animal Health Aurinia Pharmaceuticals Cidara Therapeutics Rocket Pharmaceuticals (NASDAQ:RCKT) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends. Is RCKT or EVO more profitable? Rocket Pharmaceuticals has a net margin of 0.00% compared to Evotec's net margin of -26.34%. Evotec's return on equity of -21.51% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -64.92% -56.13% Evotec -26.34%-21.51%-10.54% Which has more risk & volatility, RCKT or EVO? Rocket Pharmaceuticals has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Do analysts prefer RCKT or EVO? Rocket Pharmaceuticals presently has a consensus price target of $18.60, indicating a potential upside of 451.93%. Evotec has a consensus price target of $5.93, indicating a potential upside of 59.50%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Rocket Pharmaceuticals is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Do institutionals and insiders believe in RCKT or EVO? 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 24.8% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation & earnings, RCKT or EVO? Evotec has higher revenue and earnings than Rocket Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$258.75M-$2.63-1.28Evotec$788.22M1.68-$212.18MN/AN/A Does the media prefer RCKT or EVO? In the previous week, Rocket Pharmaceuticals had 31 more articles in the media than Evotec. MarketBeat recorded 37 mentions for Rocket Pharmaceuticals and 6 mentions for Evotec. Rocket Pharmaceuticals' average media sentiment score of 0.13 beat Evotec's score of 0.08 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 2 Very Positive mention(s) 4 Positive mention(s) 29 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRocket Pharmaceuticals beats Evotec on 8 of the 13 factors compared between the two stocks. Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCKT vs. The Competition Export to ExcelMetricRocket PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$334.24M$2.93B$5.49B$9.45BDividend YieldN/A2.49%4.01%4.03%P/E Ratio-1.2820.5328.4719.90Price / SalesN/A266.81410.1985.18Price / CashN/A41.6635.9658.29Price / Book0.667.808.365.67Net Income-$258.75M-$55.10M$3.24B$258.18M7 Day Performance17.83%4.62%3.13%2.81%1 Month Performance28.14%17.99%10.98%13.53%1 Year Performance-86.45%2.21%34.54%17.68% Rocket Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCKTRocket Pharmaceuticals4.8467 of 5 stars$3.37+7.7%$18.60+451.9%-86.0%$334.24MN/A-1.28240Trending NewsEVOEvotec2.0923 of 5 stars$3.69-13.4%$5.93+60.8%-24.4%$1.31B$862.40M0.004,827High Trading VolumeSRPTSarepta Therapeutics4.77 of 5 stars$13.32-5.3%$53.50+301.7%-90.7%$1.31B$2.23B-4.951,372Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeNTLAIntellia Therapeutics4.4252 of 5 stars$12.63+4.7%$33.37+164.2%-46.7%$1.31B$57.88M-2.41600Analyst RevisionHigh Trading VolumePHVSPharvaris1.1649 of 5 stars$23.84+2.5%$36.20+51.8%+24.3%$1.25BN/A-7.9230WVEWAVE Life Sciences4.6796 of 5 stars$7.87-5.6%$20.15+156.1%+28.4%$1.22B$108.30M-9.37240CVACCureVac4.0933 of 5 stars$5.40+0.2%$6.83+26.5%+43.3%$1.21B$579.18M5.87880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.0688 of 5 stars$29.14-0.9%$24.40-16.3%+54.2%$1.18B$1.02B37.361,940Positive NewsAUPHAurinia Pharmaceuticals3.1925 of 5 stars$8.62-0.1%$11.50+33.4%+63.5%$1.17B$247.30M30.79300Positive NewsUpcoming EarningsCDTXCidara Therapeutics3.573 of 5 stars$57.05-4.9%$57.29+0.4%+424.1%$1.15B$1.27M-1.9490High Trading Volume Related Companies and Tools Related Companies EVO Competitors SRPT Competitors NTLA Competitors PHVS Competitors WVE Competitors CVAC Competitors CALT Competitors PAHC Competitors AUPH Competitors CDTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RCKT) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
